Ligand Pharmaceuticals, Inc. (LGND)
284.41
+0.31
(+0.11%)
USD |
NASDAQ |
Sep 01, 10:09
Ligand Pharmaceuticals Cash from Operations (TTM) : 131.79M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 131.79M |
| March 31, 2026 | 123.57M |
| December 31, 2025 | 49.36M |
| September 30, 2025 | 31.80M |
| June 30, 2025 | 54.95M |
| March 31, 2025 | 52.41M |
| December 31, 2024 | 96.62M |
| September 30, 2024 | 75.38M |
| June 30, 2024 | 46.71M |
| March 31, 2024 | 33.37M |
| December 31, 2023 | 48.63M |
| September 30, 2023 | 94.98M |
| June 30, 2023 | 107.83M |
| March 31, 2023 | 119.79M |
| December 31, 2022 | 137.85M |
| September 30, 2022 | 112.02M |
| June 30, 2022 | 111.56M |
| March 31, 2022 | 120.06M |
| December 31, 2021 | 78.80M |
| September 30, 2021 | 51.69M |
| June 30, 2021 | 44.41M |
| March 31, 2021 | 48.42M |
| December 31, 2020 | 54.59M |
| September 30, 2020 | 46.71M |
| June 30, 2020 | 27.77M |
| Date | Value |
|---|---|
| March 31, 2020 | -57.67M |
| December 31, 2019 | -29.34M |
| September 30, 2019 | 10.58M |
| June 30, 2019 | 43.85M |
| March 31, 2019 | 178.56M |
| December 31, 2018 | 194.06M |
| September 30, 2018 | 197.80M |
| June 30, 2018 | 198.36M |
| March 31, 2018 | 130.11M |
| December 31, 2017 | 93.57M |
| September 30, 2017 | 78.25M |
| June 30, 2017 | 69.13M |
| March 31, 2017 | 74.11M |
| December 31, 2016 | 63.00M |
| September 30, 2016 | 55.07M |
| June 30, 2016 | 46.99M |
| March 31, 2016 | 46.66M |
| December 31, 2015 | 40.47M |
| September 30, 2015 | 37.65M |
| June 30, 2015 | 30.94M |
| March 31, 2015 | 24.91M |
| December 31, 2014 | 20.57M |
| September 30, 2014 | 22.35M |
| June 30, 2014 | 18.26M |
| March 31, 2014 | 21.19M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Johnson & Johnson | 27.61B |
| Eli Lilly & Co. | 28.08B |
| Merck & Co., Inc. | 19.97B |
| Zevra Therapeutics, Inc. | 33.40M |
| Liquidia Corp. | 167.71M |